Alluvi, previously BI 4744, presents a significant advance in obesity therapy. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates impressive effectiveness in https://techonpage.com/story7638300/alluvi-a-in-depth-investigation-into-the-medication-s-possibilities